SCINAI IMMUNOTHERAPEUTICS LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-17.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-04-17
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.60M, a 41.89% decline from fiscal 2021.
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $2.76M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2022-12-31 | $1.60M 10-K · filed 2023-04-17 |
| 2021-12-31 | $2.76M 10-K · filed 2023-04-17 |